Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Tempus AI (NASDAQ: TEM) has entered a definitive agreement to acquire Personalis (NASDAQ: PSNL), valuing Personalis at an enterprise value of $1.5 billion net of Tempus’ existing stake. Personalis shareholders will receive $16.25 per share, a 6% premium to the prior Friday close and 28% to the unaffected 30‑day VWAP.
The deal is structured as a 100% stock transaction, with Tempus able to elect up to 50% of consideration in cash, financed by cash on hand and borrowings under existing credit facilities. Personalis holders will receive a floating exchange ratio of Tempus shares, capped at 0.3356 per Personalis share, to be finalized closer to closing.
The acquisition integrates Personalis’ tumor‑informed NeXT Personal MRD technology, which has Medicare coverage in three indications, into Tempus’ AI‑enabled precision oncology and multimodal data platform. According to Tempus, this expands its capabilities across the cancer care continuum and positions both companies in the emerging $20 billion MRD market. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals. Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, a 33% sequential test volume increase.
Personalis (Nasdaq: PSNL) announced it has achieved UKCA marking for its NeXT Personal Dx test, enabling clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, including England, Wales, and Scotland.
According to Personalis, UKCA marking confirms the test meets UK safety, health, and performance standards, supports its regulatory readiness, and allows multinational biopharma trials to use the same clinical-grade MRD platform across US and UK sites. The company said NeXT Personal Dx offers high sensitivity for circulating tumor DNA to track treatment response, detect residual disease, and identify early recurrence. Personalis has appointed Link Medical Solutions in London as its business partner to support commercialization and expand access to personalized MRD testing in Great Britain.
Personalis (Nasdaq: PSNL) announced its EDTA Blood Collection Kit and cfDNA Blood Collection Kit have received Class A CE-IVD marking under the EU IVDR. This clearance allows use in interventional clinical trials across the European Union and Great Britain, supporting deployment of NeXT Personal MRD testing for global drug development.
Personalis (Nasdaq: PSNL) reported new ASCO 2026 data showing its NeXT Personal MRD test delivers ultrasensitive ctDNA detection across six solid tumors, including colorectal, lung, ovarian, endometrial, melanoma and renal cell cancers.
Results highlight early relapse detection, high sensitivity and strong prognostic value across multiple clinical settings.
Personalis (Nasdaq: PSNL) will feature six clinical abstracts using its NeXT Personal ultra-sensitive ctDNA test at the ASCO 2026 Annual Meeting, May 29–June 2 in Chicago.
Data span six solid tumor types, including a TRACERx podium talk on single-digit parts-per-million ctDNA detection in early-stage NSCLC.
Personalis (Nasdaq: PSNL) announced that CMS MolDX has issued a fourth Medicare coverage decision for its NeXT Personal MRD test, expanding use to monitor response to neoadjuvant therapy in Stage II-III TNBC and HER2+ breast cancer.
The decision, supported by the prospective PREDICT-DNA study of 227 patients at over 24 US cancer centers, extends coverage from post-surgical surveillance into active treatment monitoring. Study data showed that ultrasensitive ctDNA detection, often below 100 PPM, enabled accurate tracking of therapy response and prediction of long-term outcomes.
Personalis (Nasdaq: PSNL) announced participation in two upcoming investor conferences focused on healthcare and institutional investors.
Management will attend the Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, and the Jefferies 2026 Global Healthcare Conference on June 3, 2026.
Personalis (Nasdaq: PSNL) announced that CMS’ MolDX program has expanded Medicare coverage for its NeXT Personal MRD test to include immunotherapy monitoring in patients with late-stage solid tumors.
According to Personalis, this decision is supported by VHIO data showing ultrasensitive detection, tracking up to ~1,800 mutations with sensitivity to 1 part per million.
Personalis (Nasdaq: PSNL) reported Q1 2026 results and reaffirmed full‑year 2026 guidance. Clinical test volume rose 258% YoY to 7,815 tests and clinical revenue reached $1.4M. Company secured Medicare coverage for lung cancer surveillance and launched the Real‑Time Variant Tracker for NeXT Personal.
Q1 revenue was $15.5M, cash ~$233.2M, and full‑year revenue guidance is $78.0–$80.0M with expected clinical volume of 43,000–45,000 tests.
Personalis (Nasdaq: PSNL) will release its first quarter 2026 financial results on Thursday, May 7, 2026. A conference call and webcast will be held the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Domestic dial-in is 877-451-6152, international dial-in is 201-389-0879, and a live webinar and replay will be available via the Events section at investors.personalis.com.